PRIMARY HEMOSTATIC SYSTEM CONDITION IN MUCOVISCIDOSIS IN CHILDREN
https://doi.org/10.15690/pf.v11i1.899
Abstract
The article presents results of a study of platelet hemostasis in children with mucoviscidosis. Motionless and viscous mucus becomes infected with various pathogenic and opportunistic microbes in the setting of disturbed mucociliary clearance; when inflammation becomes chronic, endothelial dysfunction and platelet aggregation disorder may provoke development of bloodstream complications. Early diagnostics of pathologic changes in primary hemostasis is important for therapy and disease prognosis.
About the Authors
O. B. Gordeeva
Scientific Center of Children’s Health
Russian Federation
MD, senior research scientist at the laboratory of experimental immunology and virology of the Scientific Center of Children’s Health
Russian Federation
MD, senior research scientist at the laboratory of experimental immunology and virology of the Scientific Center of Children’s Health
V. V. Botvinyeva
Scientific Center of Childrens Health, Moscow, Russian Federation
Russian Federation
Russian Federation
O. I. Simonova
Scientific Center of Childrens Health, Moscow, Russian Federation
Russian Federation
Russian Federation
L. S. Namazova-Baranova
Scientific Center of Childrens Health, Moscow, Russian Federation
First Sechenov Moscow State Medical University of the Ministry of Health of the Russian Federation
Pirogov Russian National Medical Research University, Moscow
Russian Federation
Russian Federation
Y. V. Gorinova
Scientific Center of Childrens Health, Moscow, Russian Federation
Russian Federation
Russian Federation
E. L. Korolkova
Scientific Center of Childrens Health, Moscow, Russian Federation
Russian Federation
Russian Federation
M. A. Soloshenko
Scientific Center of Childrens Health, Moscow, Russian Federation
Russian Federation
Russian Federation
A. K. Gevorkyan
Scientific Center of Childrens Health, Moscow, Russian Federation
Russian Federation
Russian Federation
References
1. Kapranov N.I. Sovremennye aspekty mukovistsidoza [Modern Aspects of Mucoviscidosis]. Materialy X Natsional'nogo kongressa «Mukovistsidoz u detei i vzroslykh» (Proceedings of 10th National Congress “Mucoviscidosis in Children and Adults”). 2011. pp. 12–15.
2. Vernooy J. H., Kucukaycan M., Jacobs J. A. Local and systemic inflammation in patients with chronic obstructive pulmonary disease: soluble tumor necrosis factor receptors are increased in sputum. Am. J. Respir. Crit Care Med. 2002; 166: 1218–1224.
3. Belotskii S.M., Avtalion R.G. Vospalenie: mobilizatsiya kletok i klinicheskie effekty [Inflammation: Cell Mobilization and Clinical Effects]. Moscow, 2008. 240 p.
4. Hodson M., Geddes D. Cystic fibrosis. Chapman, London, 1995. 439 p.
5. Starovoitova E.V., Botvin'eva V.V., Fedorov A.M., Tatochenko V.K., Bakradze M.D., Darmanyan A.S. Comparative description of leukocytosis, C-reactive protein and procalcitonin levels at differential diagnostics of acute tonsillites in children. Pediatricheskaya farmakologiya = Pediatric pharmacology. 2007; 4 (33): 45–49.
6. , O'Sullivan B. P., Linden M. D., Frelinger A. L., Barnard M. R., Spencer-Manzon M. Platelet activation in cystic fibrosis. Blood. 2005; 105 (12): 4635–4661.
7. George P. M., Banya W., Pareek N., Bilton D., Cullinan P. M., Hodson M. E. Improved survival at low lung function in cystic fibrosis: cohort study from 1990 to 2007. BMJ. 2011; 342: d1008.
8. Simonova O.I., Solov'eva Yu.V., Vasil'eva E.M. A mucolytic with anti-inflammatory properties for children with mucoviscidosis: dornase alfa. Pediatricheskaya farmakologiya = Pediatric pharmacology. 2012; 9 (6): 85–90.
Review
For citations:
Gordeeva O.B., Botvinyeva V.V., Simonova O.I., Namazova-Baranova L.S., Gorinova Y.V., Korolkova E.L., Soloshenko M.A., Gevorkyan A.K. PRIMARY HEMOSTATIC SYSTEM CONDITION IN MUCOVISCIDOSIS IN CHILDREN. Pediatric pharmacology. 2014;11(1):66-68. https://doi.org/10.15690/pf.v11i1.899
Views:
710
Email this article 